|Other names||Nebostinel; N-(4,4-Dimethylcyclohexyl)-L-α-glutamine|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||256.346 g·mol−1|
|3D model (JSmol)|
Neboglamine (INN) (developmental code names CR-2249, XY-2401), formerly known as nebostinel, is a positive allosteric modulator of the glycine site of the NMDA receptor which is under investigation for Rottapharm for the treatment of schizophrenia and cocaine dependence. It shows cognition- and memory-enhancing effects in animal models. As of June 2015, it is in phase II clinical trials for both schizophrenia and cocaine abuse.